3篇
您的检索式：作者名="Matteo Bulati"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mesenchymal stromal cell secretome in liver failure:Perspectives on COVID-19 infection treatment显示文摘Due to their immunomodulatory potential and release of trophic factors that promote healing,mesenchymal stromal cells(MSCs)are considered important players in tissue homeostasis and regeneration.MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage.Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome,including the extracellular vesicles,representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis.The recent outbreak of respiratory syndrome coronavirus,caused by the newly identified agent severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has forced scientists worldwide to use all available instruments to fight the infection,including the inflammatory cascade caused by this pandemic disease.The use of MSCs is a valid approach to combat organ inflammation in different compartments.In addition to the lungs,which are considered the main inflammatory target for this virus,other organs are compromised by the infection.In particular,the liver is involved in the inflammatory response to SARS-CoV-2 infection,which causes organ failure,leading to death in coronavirus disease 2019(COVID-19)patients.We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment,and emphasize the potential of MSCbased therapy in this clinical setting. | Cinzia Maria Chinnici Giovanna Russelli Matteo Bulati Vitale Miceli Alessia Gallo Rosalia Busà Rosaria Tinnirello Pier Giulio Conaldi Gioacchin Iannolo | 2021 | World Journal of Gastroenterology2021，27，17： | 1 |
| 2 | Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells:Potential implications for their clinical use显示文摘Mesenchymal stromal/stem cells(MSCs)have shown significant therapeutic potential,and have therefore been extensively investigated in preclinical studies of regenerative medicine.However,while MSCs have been shown to be safe as a cellular treatment,they have usually been therapeutically ineffective in human diseases.In fact,in many clinical trials it has been shown that MSCs have moderate or poor efficacy.This inefficacy appears to be ascribable primarily to the heterogeneity of MSCs.Recently,specific priming strategies have been used to improve the therapeutic properties of MSCs.In this review,we explore the literature on the principal priming approaches used to enhance the preclinical inefficacy of MSCs.We found that different priming strategies have been used to direct the therapeutic effects of MSCs toward specific pathological processes.Particularly,while hypoxic priming can be used primarily for the treatment of acute diseases,inflammatory cytokines can be used mainly to prime MSCs in order to treat chronic immune-related disorders.The shift in approach from regeneration to inflammation implies,in MSCs,a shift in the production of functional factors that stimulate regenerative or anti-inflammatory pathways.The opportunity to fine-tune the therapeutic properties of MSCs through different priming strategies could conceivably pave the way for optimizing their therapeutic potential. | Vitale Miceli Giovanni Zito Matteo Bulati Alessia Gallo Rosalia Busà Gioacchin Iannolo Pier Giulio Conaldi | 2023 | World Journal of Stem Cells2023，15，5： | 1 |
| 3 | Immunosenescence, inflammation and Alzheimer's disease 显示文摘 | Adriana Martorana Matteo Bulati Silvio Buffa | 2012 | Longev Healthspan2012，1，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员